| Not Yet Recruiting | Mass Balance Study of [14C] LPM3770164 in Healthy Participants Huntington Disease | Phase 1 | 2026-04-30 |
| Not Yet Recruiting | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Metastatic Colorectal Cancer (mCRC) | Phase 1 / Phase 2 | 2026-03-31 |
| Not Yet Recruiting | A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizoph Schizophrenia | Phase 2 | 2026-03-31 |
| Enrolling By Invitation | To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy C Major Depressive Disorder | Phase 1 | 2025-10-28 |
| Recruiting | A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | 2025-08-20 |
| Active Not Recruiting | A Food Effect Study of LY03020 in Healthy Subjects Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | 2025-07-30 |
| Not Yet Recruiting | A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia | Phase 1 | 2025-05-01 |
| Not Yet Recruiting | Effect of Food and Age on the Pharmacokinetics of LY03017 Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia | Phase 1 | 2025-02-01 |
| Recruiting | Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia Tardive Dyskinesia (TD) | Phase 1 / Phase 2 | 2025-01-14 |
| Active Not Recruiting | Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoin Assisted Reproduction | Phase 2 | 2024-10-09 |
| Recruiting | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC Relapsed Small Cell Lung Cancer | Phase 3 | 2024-09-14 |
| Completed | A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | 2024-08-19 |
| Completed | Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets Huntington Disease, Tardive Dyskinesia | Phase 1 | 2024-07-31 |
| Not Yet Recruiting | To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets Major Depressive Disorder | Phase 4 | 2024-05-30 |
| Not Yet Recruiting | A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia | Phase 1 | 2024-05-10 |
| Recruiting | First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. Advanced Solid Tumor | Phase 1 | 2024-03-12 |
| Recruiting | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer Relapsed Small Cell Lung Cancer | Phase 3 | 2024-03-03 |
| Recruiting | Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pai Pain, Postoperative | Phase 2 | 2024-01-26 |
| Completed | Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects Tardive Dyskinesia, Huntington Disease | Phase 1 | 2023-12-19 |
| Recruiting | A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Gener Generalized Anxiety Disorder | Phase 3 | 2023-07-12 |
| Completed | Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) Healthy | Phase 1 | 2023-05-02 |
| Unknown | Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex Prostate Cancer | Phase 1 | 2023-05-01 |
| Active Not Recruiting | Comparative Efficacy, Safety, PK, and Immunogenicity Study Osteoporosis, Postmenopausal | Phase 3 | 2023-04-05 |
| Completed | Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pai Pain, Postoperative | Phase 2 | 2022-11-25 |
| Completed | Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer Advanced Breast Cancer | Phase 1 | 2022-05-17 |
| Completed | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subj Huntington Disease, Tardive Dyskinesia | Phase 1 | 2022-02-25 |
| Completed | An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects Healthy | Phase 1 | 2021-11-08 |
| Completed | Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Schizophrenia, Psychotic Disorders, Mood Disorders | Phase 1 | 2021-09-08 |
| Unknown | Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors Bone Metastases From Solid Tumors | Phase 3 | 2021-04-30 |
| Enrolling By Invitation | Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advance Advanced Solid Tumors | Phase 1 / Phase 2 | 2021-04-22 |
| Completed | A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Sa Healthy | Phase 1 | 2021-03-09 |
| Completed | A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects Healthy | Phase 1 | 2021-02-25 |
| Completed | Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® Prostate Cancer | Phase 1 | 2021-02-04 |
| Unknown | to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteer Parkinson's Disease | Phase 1 | 2021-02-02 |
| Completed | Relative Bioavailability of LY03010 Compared to Listed Drug Schizophrenia, Psychotic Disorders, Mood Disorders | Phase 1 | 2021-01-13 |
| Unknown | A Study to Evaluate LY06006 and Prolia in Healthy Adults Healthy Adults | Phase 1 | 2020-12-09 |
| Completed | Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients Advanced Solid Tumor | Phase 1 | 2020-11-24 |
| Unknown | A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects Covid19 | Phase 1 | 2020-11-10 |
| Unknown | A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） Age Related Macular Degeneration | Phase 3 | 2020-11-01 |
| Completed | Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® Breast Cancer | Phase 3 | 2020-10-15 |
| Completed | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2020-09-28 |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD Parkinson Disease | Phase 1 | 2020-07-07 |
| Completed | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Singl Parkinson Disease | Phase 1 | 2020-06-02 |
| Completed | A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD Parkinson Disease | Phase 3 | 2020-05-11 |
| Completed | Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injecti Schizophrenia Patients | Phase 1 | 2020-01-22 |
| Completed | Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® Prostate Cancer | Phase 3 | 2020-01-06 |
| Unknown | A Study to Evaluate LY01011 and Xgeva® in Healthy Adults Healthy Adults | Phase 1 | 2019-12-16 |
| Unknown | A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk Postmenopausal Osteoporosis | Phase 3 | 2019-06-30 |
| Completed | Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2019-02-15 |
| Completed | A Relative Bioavailability Food Effect Study of LY03005 Major Depressive Disorder | Phase 1 | 2019-01-16 |
| Unknown | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors Solid Tumor | Phase 1 | 2018-12-18 |
| Completed | A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patie Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder | Phase 1 | 2018-12-12 |
| Completed | A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatm Major Depressive Disorder (MDD) | Phase 3 | 2018-12-05 |
| Completed | A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro Parkinson Disease | Phase 1 | 2018-11-09 |
| Completed | A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients Parkinson Disease | Phase 1 | 2018-11-05 |
| Completed | A Study of LY03005 vs Pristiq Major Depressive Disorder | Phase 1 | 2018-06-19 |
| Completed | Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease Parkinson Disease | Phase 1 | 2018-05-15 |
| Unknown | A Study to Evaluate the Denosumab in Healthy Adults Healthy Adults | Phase 1 | 2018-01-10 |
| Completed | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer Cancer of Prostate | Phase 1 | 2017-12-22 |
| Completed | Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® Major Depressive Disorder | Phase 1 | 2017-11-27 |
| Unknown | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects Wi Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent | Phase 3 | 2017-11-27 |
| Completed | A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease Parkinson Disease | Phase 1 | 2017-10-10 |
| Completed | Pilot BA Study of New LY03005 vs Pristiq Major Depression | Phase 1 | 2016-12-07 |
| Completed | Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Parkinson's Disease | Phase 1 | 2016-05-01 |
| Completed | Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers Lipid Metabolism Disorder | Phase 1 | 2015-11-01 |
| Completed | Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Tre Major Depressive Disorder | Phase 1 | 2015-10-09 |
| Completed | Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics o Major Depressive Disorder, Recurrent, Unspecified | Phase 1 | 2014-10-01 |
| Completed | Bioavailability of LY03004 and Risperdal® Consta® Schizophrenia, Schizoaffective Disorder | Phase 1 | 2014-09-01 |
| Completed | An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophre Schizophrenia, Schizoaffective Disorder | Phase 1 | 2014-07-01 |
| Completed | Safety, Tolerability and Pharmacokinetics Study of LY03005 Major Depressive Disorder | Phase 1 | 2014-02-01 |
| Completed | A Study of LY03003 in Patients With Early-stage Parkinson's Disease Parkinson Disease | Phase 1 | 2013-11-22 |
| Completed | Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease Parkinson's Disease | Phase 1 | 2013-10-01 |
| Completed | A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003 Parkinson Disease | Phase 1 | 2013-03-15 |
| Completed | Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder Schizophrenia, Schizoaffective Disorder | Phase 1 | 2013-03-01 |